Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).
Zitouni J, Bursztejn AC, Belloni Fortina A, Beauchet A, Di Lernia V, Lesiak A, Thomas J, Topkarci Z, Murashkin N, Brzezinski P, Torres T, Chiriac A, Luca C, McPherson T, Akinde M, Maruani A, Epishev R, Vidaurri de la Cruz H, Luna PC, Amy de la Bretêque M, Lasek A, Bourrat E, Bachelerie M, Mallet S, Steff M, Bellissen A, Neri I, Zafiriou E, van den Reek JMPA, Sonkoly E, Mahil SK, Smith CH, Flohr C, Bachelez H, Mahé E; Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Società Italiana di Dermatologia Pediatrica (S.I.Der.P.).
Zitouni J, et al.
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2076-2086. doi: 10.1111/jdv.18361. Epub 2022 Jul 6.
J Eur Acad Dermatol Venereol. 2022.
PMID: 35748102
Free PMC article.
Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. ...DISCUSSION: Biologics appear to be safe with no increased risk of severe …
Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, CO …